Foundations Investment Advisors LLC Has $1.55 Million Holdings in Merck & Co., Inc. $MRK

Foundations Investment Advisors LLC trimmed its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 31.3% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 18,426 shares of the company’s stock after selling 8,405 shares during the period. Foundations Investment Advisors LLC’s holdings in Merck & Co., Inc. were worth $1,546,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of MRK. DLD Asset Management LP acquired a new stake in shares of Merck & Co., Inc. in the 2nd quarter valued at about $2,889,340,000. Norges Bank acquired a new position in Merck & Co., Inc. during the 2nd quarter worth approximately $2,858,570,000. Franklin Resources Inc. boosted its holdings in Merck & Co., Inc. by 23.5% in the second quarter. Franklin Resources Inc. now owns 27,032,601 shares of the company’s stock worth $2,139,901,000 after acquiring an additional 5,135,748 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its stake in Merck & Co., Inc. by 35.5% in the second quarter. Arrowstreet Capital Limited Partnership now owns 19,456,096 shares of the company’s stock valued at $1,540,145,000 after acquiring an additional 5,094,088 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in Merck & Co., Inc. by 9.4% in the second quarter. Charles Schwab Investment Management Inc. now owns 53,865,466 shares of the company’s stock valued at $4,263,991,000 after acquiring an additional 4,636,183 shares during the period. Institutional investors own 76.07% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on MRK. Bank of America increased their target price on Merck & Co., Inc. from $105.00 to $120.00 and gave the stock a “buy” rating in a report on Monday, December 15th. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Merck & Co., Inc. from $110.00 to $111.00 and gave the company a “hold” rating in a research note on Tuesday, November 18th. Citigroup boosted their target price on shares of Merck & Co., Inc. from $110.00 to $115.00 and gave the stock a “neutral” rating in a research report on Tuesday. Zacks Research cut shares of Merck & Co., Inc. from a “hold” rating to a “strong sell” rating in a research report on Friday, January 9th. Finally, Morgan Stanley lifted their price target on Merck & Co., Inc. from $100.00 to $102.00 and gave the company an “equal weight” rating in a research note on Friday, December 12th. Eight investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Merck & Co., Inc. currently has a consensus rating of “Hold” and a consensus price target of $114.53.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Zacks highlights strong Keytruda demand and new product launches as key upside drivers into Q4 results, supporting longer‑term revenue growth and helping sentiment today. Buy, Sell or Hold MRK Stock: Key Factors to Watch Before Q4 Earnings
• Positive Sentiment: Insider/“smart money” activity: Chirfi Guindo bought roughly $1.06M of MRK stock — a buy by an institutional insider can signal confidence and attract momentum buyers. Smart Money Move: Chirfi Guindo Grabs $1.06M Worth Of Merck & Co Stock
• Positive Sentiment: Zacks’ market recap notes MRK outperformed while the broader market dipped, indicating relative strength and sector‑specific buying interest. Why the Market Dipped But Merck (MRK) Gained Today
• Neutral Sentiment: Analyst notes and sector coverage (Globe and Mail) provide mixed, mostly informational views on Merck alongside peers—useful for context but not a clear directional trigger. Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Waters (WAT)
• Neutral Sentiment: Additional analyst commentary comparing MRK with UnitedHealth provides sector perspective but no new catalyst. Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and UnitedHealth (UNH)
• Neutral Sentiment: Zacks’ primer on Wall Street estimates and key metrics ahead of Q4 is a useful reference for modeling MRK’s upcoming quarter but doesn’t itself move the needle. Curious about Merck (MRK) Q4 Performance? Explore Wall Street Estimates for Key Metrics
• Neutral Sentiment: Zacks notes MRK is a trending stock on its platform—higher retail/institutional attention increases liquidity and volatility risk but is not a directional catalyst by itself. Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
• Negative Sentiment: Zacks warns that declining analyst estimates and rising M&A‑related costs could depress near‑term results and investor sentiment—key risk ahead of earnings. Buy, Sell or Hold MRK Stock: Key Factors to Watch Before Q4 Earnings
• Negative Sentiment: Brokerage consensus is an average “Hold” rating, indicating limited near‑term upgrade potential and less bullish analyst conviction. Merck & Co., Inc. (NYSE:MRK) Given Average Rating of “Hold” by Brokerages

Merck & Co., Inc. Price Performance

Merck & Co., Inc. stock opened at $110.24 on Friday. Merck & Co., Inc. has a 52 week low of $73.31 and a 52 week high of $112.90. The company’s 50 day moving average price is $105.20 and its two-hundred day moving average price is $91.87. The company has a quick ratio of 1.44, a current ratio of 1.66 and a debt-to-equity ratio of 0.77. The stock has a market cap of $273.62 billion, a P/E ratio of 14.56, a P/E/G ratio of 1.52 and a beta of 0.29.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Tuesday, February 3rd. The company reported $1.94 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.08 by ($0.14). Merck & Co., Inc. had a net margin of 29.63% and a return on equity of 44.54%. On average, equities analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be paid a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date is Monday, March 16th. Merck & Co., Inc.’s payout ratio is presently 44.91%.

Insider Activity at Merck & Co., Inc.

In related news, EVP David Michael Williams sold 8,614 shares of the business’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $83.59, for a total value of $720,044.26. Following the transaction, the executive vice president directly owned 24,578 shares of the company’s stock, valued at approximately $2,054,475.02. The trade was a 25.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.13% of the stock is owned by insiders.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.